Follow us on LinkedIn.
Cambridge Molecular Diagnostics Limited (SwiftDx) announces the launch of a new lateral flow test for the detection of Mycoplasma contamination. The innovative, easy-to-use, rapid test uses an adapted PCR method and provides accurate results within minutes, making it a valuable tool for laboratories and manufacturers in academia and the biotech and pharmaceutical industries. The test has been fully validated, including evaluation within the University of Cambridge.
The new lateral flow test will be a valuable tool for researchers and biomanufacturers to ensure the quality and integrity of their cell culture systems, and ultimately improve the reproducibility.
“SwiftDx has reached a significant milestone with the launch of their first commercial product,” said Mike O’Connell, CEO at Isosceles Finance and iFD. “We are delighted to have supported them in transitioning from a research-based company to commercialisation. With some exciting progress in products for the early detection of human illnesses in the pipeline, SwiftDX has the opportunity to be a very significant company in every way.”
iFD supported this transition through three EIS equity rounds and by securing convertible loan notes from two investors, including the Future Fund. These investments allowed the company to continue its R&D program and complete the development and commercial launch of the new lateral flow test for the detection of Mycoplasma contamination.
“We are thrilled to offer this innovative test to our customers,” said Professor Denis Kinane, Chairman at Cambridge Molecular Diagnostics Limited. “Mycoplasma contamination is a major concern in the biotech and pharmaceutical industries, and the SwiftDx Mycoplasma Detection Kit provides a fast, accurate and cost-effective solution. We believe that the convenience and speed of the SwiftDx Mycoplasma Detection Kit is game-changing for anyone using cell culture, from academic institutions to vaccine manufacturers. This product will help these organisations to stop mycoplasma contamination in its tracks.”
Related link | Meet some of our other clients
(Image Source: iStock)